|
Jul 30
|
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Jul 28
|
Exploring High Growth Tech Stocks In The US Market
|
|
Jul 23
|
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
|
|
Jul 17
|
Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196%
|
|
Jul 10
|
Arcutis Biotherapeutics Stock Scores RS Rating Upgrade
|
|
Jun 26
|
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
|
|
Jun 23
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jun 15
|
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
|
|
Jun 11
|
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis
|
|
Jun 10
|
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
|
|
Apr 17
|
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
|
|
Apr 10
|
Arcutis Announces Chief Financial Officer Transition
|
|
Apr 3
|
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?
|
|
Apr 3
|
Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?
|
|
Apr 2
|
Sector Update: Health Care Stocks Advance in Late Afternoon Trading
|
|
Apr 2
|
Arcutis and Padagis Agree to Stay Patent Lawsuit
|
|
Jan 16
|
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade
|
|
Jan 3
|
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
|
|
Oct 25
|
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
|
|
Oct 24
|
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
|